afinitor
novartis new zealand ltd - everolimus 5mg; ; - tablet - 5 mg - active: everolimus 5mg excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - the treatment of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not amenable to surgery. the evidence is based on change in sega volume. further clinical benefit, such as improvement of disease-related symptoms, has not been demonstrated.
afinitor tablet
novartis pharmaceuticals canada inc - everolimus - tablet - 10mg - everolimus 10mg - antineoplastic agents
afinitor 2.5mg tablets
novartis pharmaceuticals uk ltd - everolimus - tablet - 2.5mg
afinitor tablets 10mg
novartis pharma services inc p.o.box 46057 00100 nairobi - everolimus - tablet - 10mg - other antineoplastic agents: protein kinase
afinitor 10 mg 30 comprimits
afinitor tablet 2.5 mg
novartis (singapore) pte ltd - everolimus +0.2% bht - tablet - 2.50 mg - everolimus +0.2% bht 2.50 mg
afinitor tablet 10mg
novartis (singapore) pte ltd - everolimus - tablet - 10.00mg - everolimus 10.00mg
afinitor tablet 5mg
novartis (singapore) pte ltd - everolimus - tablet - 5.00mg - everolimus 5.00mg
afinitor tablets
novartis pharma stein ag - everolimus - tablets - 5mg
afinitor tablets
novartis pharma stein ag - everolimus - tablets - 2,5mg